chemotherapy for primary bone sarcoma over 41 except for Ewing sarcoma

chemotherapy for primary bone sarcoma over 41 except for Ewing sarcoma - chemotherapy for primary bone sarcoma over 41

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023089

Enrollment

200

Registered

2016-07-10

Start date

2016-07-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary bone sarcoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: data from bone tumor registry in Japan, registered in 2006 to 2012 >41 years old osteosarcoma, undifferentiated high grade pleomorphic sarcoma, dedifferentiated chondrosarcoma, leiomyosarcoma, hemangioendothelioma, fibrosarcoma, malignant giant cell tumor, clear cell chondrosarcoma, undifferentiated sarcoma, hemangiopericytoma, liposarcoma, and malignant mesenthelioma

Exclusion criteria

Exclusion criteria: <41 years old low grade malignancy

Design outcomes

Primary

Measure	Time frame
5 year overall survival	—

Secondary

Measure	Time frame
5 year progression free survival	—

Countries

Japan

Contacts

Public ContactAkihito Nagano

Gifu Gfraduate University school of medicine The department of Orthopaedic surgery

a-nagano@lucky.odn.ne.jp058-230-6333

Outcome results